title: [Leukinferon in combined therapy for acute pulmonary tuberculosis].
abstract: Experiments on 140 CBA and C57BL/6 mice and studies of 163 patients with acute pulmonary tuberculosis have indicated that leukinferon has a immunomodulating effect on morphological reactions in the lung and on the clinical course of the disease. They have shown that leukinferon plays an important role in the activation of exudate macrophages and in the acceleration of their differentiation in experimental tuberculosis and that there is a rapid elimination of Mycobacterium tuberculosis from the involved organs without production of the L-forms of the causative agent when immunomodulation is used. At months 2-3, the patients with acute pulmonary tuberculosis showed the accelerated processes of detoxification, abacillation, infiltrate resolution, and decay cavity closure during hemo- and immunomodulation with the normalized production of cytokines (gamma-interferon and tumor necrosis factor-alpha). During 6-month therapy, a severe pulmonary process was arrested in 84% of cases and some patients were operated on (76% in the comparison group). The morphological effect of leukinferon was to increase mononuclear infiltration and to normalize a lung connective tissue response, by further decreasing the rate of inflammation.
authors.forename: V V
authors.initials: VV
authors.lastname: Erokhin
authors.forename: V Iu
authors.initials: VIu
authors.lastname: Mishin
authors.forename: V G
authors.initials: VG
authors.lastname: Makiev
authors.forename: O P
authors.initials: OP
authors.lastname: Dryga
authors.forename: L E
authors.initials: LE
authors.lastname: Gedymin
authors.forename: L N
authors.initials: LN
authors.lastname: Lepekha
authors.forename: D L
authors.initials: DL
authors.lastname: Beliaev
authors.forename: A A
authors.initials: AA
authors.lastname: Babaiants
mesh_terms: D000208:Acute Disease; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000995:Antitubercular Agents / Q000627:therapeutic use*; D017252:CD3 Complex / Q000276:immunology; D016207:Cytokines / Q000627:therapeutic use*; D018450:Disease Progression; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology
chemical_list: D000276:Adjuvants, Immunologic; D000995:Antitubercular Agents; D017252:CD3 Complex; D016207:Cytokines; D004338:Drug Combinations; D007370:Interferon Type I; C062252:leukinferon